High dose rate brachytherapy using molds after chemoradiotherapy for oral cavity cancer

被引:10
|
作者
Chatani, Masashi [1 ]
Tsuboi, Kazuki [1 ]
Yagi, Masayuki [1 ]
Fujiwara, Kanta [1 ]
Tachimoto, Rika [1 ]
Yoshioka, Hideo
机构
[1] Osaka Rosai Hosp, Dept Radiat Oncol, Kita Ku, Sakai, Osaka, Japan
关键词
Oral cancer; Mold radiotherapy; Ir high dose rate brachytherapy; UTERINE CERVIX; RADIOTHERAPY; CARCINOMAS;
D O I
10.1007/s11604-011-0005-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to investigate the role of the combined use of customized molds and a high dose rate (HDR) remote afterloading brachytherapy apparatus with a Ir-192 microsource in the treatment of superficial oral carcinomas after chemoradiotherapy. Nine patients with oral squamous cell carcinoma who were treated using this combined technique were analyzed retrospectively. The primary sites of the tumors were the mouth floor, gingiva, and soft palate. For each patient, a customized mold was fabricated in which 2-3 afterloading catheters were placed for the Ir-192 source. Three to eight fractions of 3 Gy, 5 mm below the mold surface, were given following external radiotherapy of 24-50 Gy/2 Gy combined with chemotherapy (peplomycin or taxotere). The total dose of HDR brachytherapy ranged from 9 to 24 Gy. The 2-year local control probability was 100% and the 2-year cause-specific survival rate was 100%. No serious complications (i.e., ulcer or bone exposure) have been observed thus far during the follow-up period of 29-120 months. HDR brachytherapy using the mold technique after chemoradiotherapy is a safe and excellent method for selected early and superficial oral cavity cancers.
引用
收藏
页码:40 / 44
页数:5
相关论文
共 50 条
  • [41] High dose rate brachytherapy of localized prostate cancer
    Deger, S
    Boehmer, D
    Türk, I
    Roigas, J
    Wernecke, KD
    Wiegel, T
    Hinkelbein, W
    Dinges, S
    Budach, V
    Loening, SA
    EUROPEAN UROLOGY, 2002, 41 (04) : 420 - 426
  • [42] High dose rate brachytherapy in the treatment of cervical cancer
    Petereit, DG
    VOLUME & KINETICS IN TUMOR CONTROL & NORMAL TISSUE COMPLICATIONS, 1998, : 148 - 170
  • [43] Concurrent chemoradiotherapy for cervical cancer in a single institution: High-dose rate brachytherapy vs helical tomotherapy
    Kim, S.
    Ryu, K. J.
    Lee, S.
    Song, J. Y.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 40 - 41
  • [44] High dose rate brachytherapy for superficial cancer of the esophagus
    Maingon, P
    D'Hombres, A
    Truc, G
    Barillot, I
    Michiels, C
    Bedenne, L
    Horiot, JC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (01): : 71 - 76
  • [45] Lip cancer treatment with high dose rate brachytherapy
    Guinot, JL
    Arribas, L
    Chust, ML
    Mengual, JL
    Miragall, EG
    Carrascosa, M
    Escolar, PP
    Crispín, V
    Guardino, C
    RADIOTHERAPY AND ONCOLOGY, 2003, 69 (01) : 113 - 115
  • [46] High dose rate brachytherapy in the management of cervix cancer
    Nanavati, P
    Shaffer, J
    Crispens, M
    Wynstra, J
    Elliott, E
    Maxey, P
    Frierdich, C
    VanderMeersch, S
    RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S7 - S8
  • [47] High dose rate brachytherapy in the treatment of prostate cancer
    Vicini, F
    Vargas, C
    Gustafson, G
    Edmundson, G
    Martinez, A
    WORLD JOURNAL OF UROLOGY, 2003, 21 (04) : 220 - 228
  • [48] High-dose-rate interstitial brachytherapy in oral cancer Its impact on quality of life
    Bajwa, Harjot Kaur
    Singareddy, Rohith
    Alluri, Krishnam Raju
    BRACHYTHERAPY, 2016, 15 (03) : 381 - 386
  • [49] Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy
    Raleigh, David R.
    Hsu, I-Chow
    Braunstein, Steve
    Chang, Albert J.
    Simko, Jeffry P.
    Roach, Mack, III
    BRACHYTHERAPY, 2015, 14 (02) : 185 - 188
  • [50] Efficacy/toxicity after high dose rate brachytherapy as monotherapy for localized prostate cancer
    Novikov, S.
    Kanaev, S.
    Gotovchikova, M.
    Novikov, R.
    Ilin, D.
    Girshovitch, M.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S586 - S587